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Tumor cell growth and survival can often be impaired by inactivating a single oncogen – a
phenomenon that has been called as “oncogene addiction.” It is in such scenarios that
molecular targeted therapies may succeed. Among known oncogenes, the epidermal
growth factor receptor (EGFR) has become the target of different cancer therapies. So
far, however, the clinical beneﬁt from EGFR-targeted therapies has been rather limited. A
critical review of the large amount of clinical data obtained with anti-EGFR agents, carried
out from the perspective of the oncogene addiction concept, may help to understand the
causes of the unsatisfactory results. In this articlewe intend to do such an exercise taking as
basis for the analysis a few case studies of anti-EGFR agents that are currently in the clinic.
There, the “EGFR addiction” phenomenon becomes apparent in high-responder patients.
We further discuss how the concept of oncogene addiction needs to be interpreted on
the light of emerging experimental evidences and ideas; in particular, that EGFR addiction
may reﬂect the interconnection of several cellular pathways. In this regard we set forth
several hypotheses; namely, that requirement of higher glucose uptake by hypoxic tumor
cells may reinforce EGFR addiction; and that chronic use of EGFR-targeted antibodies in
EGFR-addicted tumors would induce stable disease by reversing the malignant phenotype
of cancer stem cells and also by sustaining an anti-tumorT cell response. Finally, we discuss
possible reasons for the failure of certain combinatorial therapies involving anti-EGFR
agents, arguing that some of these agents might produce either a negative or a positive
trans-modulation effect on other oncogenes. It becomes evident that we need operational
deﬁnitions of EGFR addiction in order to determine which patient populations may beneﬁt
from treatment with anti-EGFR drugs, and to improve the design of these therapies.
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INTRODUCTION
The concept of “oncogene addiction,” as enunciated by Weinstein
(2002), arises from a series of experimental and clinical evidences
showing that “cancer cells are often “addicted to” (that is, physio-
logically dependent on) the continued activity of speciﬁc activated
or over-expressed oncogenes for maintenance of their malignant
phenotype.”This concept provides a theoretical framework,whose
bases stand both at the molecular and systems biology levels, that
supports the targeted therapy approach in cancer treatment.
Among known oncogenes, the epidermal growth factor recep-
tor (EGFR) accounts for a signiﬁcant number of the molecular
targeting agents being used today in the clinic. These agents are
either small-molecule tyrosine kinase inhibitors (STKIs), which
block receptor signaling by interfering with ATP binding to
the receptor (Quatrale et al., 2011), or monoclonal antibodies
(mAbs), which bind to the extracellular region of the receptor,
inhibiting its dimerization and autophosphorylation (Schmitz and
Ferguson, 2009).
Data supporting addiction in tumors have been gathered for
a number of different oncogenes, as reviewed in Weinstein and
Joe (2006). For the EGFR in particular, positive results in clinical
trials with different antagonists have been considered as clinical
evidences of oncogene addiction, even though the clinical beneﬁts
from the use of eithermAbs or STKIs have been rather limited. The
question on which subset of cancer patients would be most ben-
eﬁted from these treatments is still under debate, and meanwhile
the use of EGFR-targeted therapies in advanced cancer patients
remains largely empirical.
A critical review of the large amount of clinical data obtained
with different anti-EGFR agents, carried out from the perspective
of the oncogene addiction concept, may help to better assess the
phenomenon of “EGFR addiction” in human tumors, interpret-
ing this addiction in a broad sense that comprises not only the
receptor itself, but also its signaling pathway (Weinstein and Joe,
2008). A deeper understanding of this phenomenon would in turn
contribute to a more rational, and therefore more effective clinical
use of EGFR antagonists.
On the other hand, the concept of oncogene addiction itself
needs to be interpreted on the light of the growing experimental
evidences and newly emerging ideas. One of the hypotheses devel-
oped over the last years is based on the existence of a tumor cell
hierarchy and suggests that tumorigenicity resides in only a small
subpopulation of cancer stem cells (Driessens et al., 2012; Nguyen
et al., 2012). Revising the concept of oncogene addiction under
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the premises of the cancer stem cell model becomes then a nec-
essary theoretical exercise. In particular, we need to gain a deeper
knowledgeon the relevanceof EGFRaddiction for tumor initiating
cells. Another emerging body of evidences indicates that intracel-
lular circuitries involving tumor metabolism and immunogenic
cell death are connected to the EGFR signaling pathway (Weihua
et al., 2008; Garrido et al., 2011a) and, therefore, they might be
also involved in the phenomenon of EGFR addiction.
Results from the clinical use of different EGFR-targeted ther-
apies lead to several relevant questions, namely: what are the
molecular and cellular bases of intrinsic or acquired resistance?
What would be the rationale for designing combinatorial ther-
apies? What are the scenarios for chronic use of anti-EGFR
agents? A better understanding of the complexity of the EGFR
signaling network in human tumors would shed light on these
questions and might contribute to establish operational deﬁ-
nitions of “addiction-predictor” biomarkers. In this article we
intend to do a hypothesis-generating exercise based on diverse
pieces of clinical data, hoping to raise a debate that ultimately
would promote both experimental and clinical research. A com-
pendium of the main hypotheses discussed in the article is given
in Box 1. The main goal at the end is to increase the effec-
tiveness of available EGFR-targeted therapies in advanced cancer
patients.
CLINICAL IMPACT OF EGFR-TARGETED THERAPIES IN TWO
CASE STUDIES: CETUXIMAB AND ERLOTINIB
Cetuximab is an EGFR-antagonistic antibody which is currently
indicated for advanced head and neck and colorectal cancer
(CRC). Cetuximab has been approved for the treatment of
locally advanced squamous cell carcinoma of the head and neck
(SCCHN) in combination with radiation therapy (RT; Bonner
et al., 2006), for recurrent or metastatic carcinomas of the head
andneck in combinationwith chemotherapy, and asmonotherapy
for recurrent or metastatic tumors of the head and neck pro-
gressing after platinum-based therapy (Vermorken et al., 2008).
This antibody is also indicated for Kras mutation-negative (wild-
type), EGFR-expressing, metastatic colorectal cancer (mCRC) in
combination with FOLFIRI for ﬁrst-line treatment (Van Cutsem
et al., 2009). It is also indicated in combination with irinote-
can for mCRC patients who are refractory to irinotecan-based
chemotherapy (Cunningham et al., 2004), and as a single agent
in CRC patients who have failed oxaliplatin and irinotecan-based
chemotherapy (Jonker et al., 2007).
Erlotinib, on the other hand, is a STKI indicated for mainte-
nance treatment in patients with advanced non-small cell lung
cancer (NSCLC) whose disease has not progressed after four
cycles of platinum-based ﬁrst-line chemotherapy (Cappuzzo et al.,
2010; Pérol et al., 2012); for treatment of advanced NSCLC after
failure of at least one prior chemotherapy regimen (Shepherd
et al., 2005); and as ﬁrst-line treatment of patients with locally
advanced pancreatic cancer, in combination with gemcitabine
(Moore et al., 2007).
In spite of these marketing approvals, the impact of both cetux-
imab and erlotinib in terms of clinical beneﬁt has been in general
limited when evaluated for the overall populations included in the
clinical trials.
BOX 1 | Summary of hypotheses.
• Oncospeciﬁc treatment, radiotherapy and chemotherapy, rein-
force EGFR addiction. Naïve addiction is reinforced by radio-
therapy in primary tumors, while adaptive addiction arises as
a resistance mechanism to radiotherapy and chemotherapy in
recurrent disease.
• Only a few markers of EGFR addiction can be already deﬁned,
each one of them for a speciﬁc tumor type and a particular dis-
ease stage. No single universal predictor biomarker is likely to
exist.
• The requirement of a higher glucose uptake by hypoxic tumor
cells reinforces EGFR addiction.
• EGFR-targeted antibody therapy generates an anti-tumor T cell
response. Chronic use of the EGFR antagonistic mAb might be
required to boost such response.
• The induction of stable disease with EGFR-targeted therapy is
due, at least partially, to reversal of the malignant phenotype of
cancer stem cells and inhibition of the epithelial-to-mesenchymal
transition.
• Resistance mechanisms to EGFR-targeted therapies may pro-
vide clues for the design of combinatorial targeted therapies.
Each tumor type, in a given disease stage, would have a
predominant intrinsic resistance mechanism.
Encouraging results were achieved with cetuximab in locore-
gionally advanced head and neck cancer. The median survival
time (MST) was 49.0 months among patients treated with cetux-
imab and RT, versus 29.3 months among those treated with RT
alone (Bonner et al., 2006). In a worse prognostic patient popu-
lation, however, subjects with recurrent or metastatic carcinomas
of the head and neck had a MST of 10.1 months if treated with
cetuximab and platinum-based chemotherapy with ﬂuorouracil
(CTP), versus 7.4 months if treated with CTP alone (Vermorken
et al., 2008). In the colorectal scenario, the addition of cetuximab
to leucovorin, ﬂuorouracil, and irinotecan (FOLFIRI) as ﬁrst-line
treatment for Kras wild-type mCRC resulted in a modest overall
survival improvement (median, 23.5 versus 20.0months;VanCut-
sem et al., 2009). In another study with subjects whose disease had
progressed within an irinotecan-based regimen, the combination
of cetuximab and irinotecan yielded a MST of 8.6 months, versus
6.9 months for the cetuximab monotherapy group (Cunningham
et al., 2004). Finally, patients with EGFR-expressing CRC, who
had been previously treatedwith ﬂuoropyrimidine, irinotecan and
oxaliplatin, had a median overall survival of 6.1 months if treated
with cetuximab, and 4.6 months if receiving supportive care alone
(Jonker et al., 2007).
Cetuximab has been evaluated also in other scenarios with-
out ending up in marketing approvals. This was the case for
the FLEX (First-Line ErbituX in lung cancer) study, which
compared cisplatin and vinorelbine plus cetuximab with cis-
platin and vinorelbine alone in the ﬁrst-line treatment of
1125 patients with EGFR-expressing, advanced NSCLC. The
study showed that the addition of cetuximab to chemother-
apy improved overall survival only from 10.1 to 11.3 months
(Pirker et al., 2009).
Clinical results with erlotinib have evidenced a similar lim-
ited impact. In a study carried out with patients with stage
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IIIB or IV NSCLC who previously went through one or two
chemotherapy regimens, the overall survival was 6.7 months
for the group treated with erlotinib, versus 4.7 months for the
placebo group (Shepherd et al., 2005). In the SATURN trial for
NSCLC patients with non-progressive disease following ﬁrst-line
platinum-doublet chemotherapy, the median progression-free
survival (PFS) was only slightly longer with erlotinib than with
placebo: 12.3 versus 11.1 weeks (Cappuzzo et al., 2010).
In a more recent clinical trial, patients with IIIB/IV NSCLC
without tumor progression after four cycles of cisplatin–
gemcitabine were randomly assigned to observation or to gem-
citabine or erlotinib. As compared to the observation group,
PFS was prolonged by gemcitabine from 1.9 to 3.8 months,
and to 2.9 months by erlotinib (Pérol et al., 2012). Thus, both
maintenance strategies resulted in poor improvements in overall
survival. Lastly, in the pancreatic setting, patients with advanced
tumors received standard gemcitabine plus erlotinib or gemc-
itabine plus placebo. The overall survival was prolonged in the
erlotinib/gemcitabine arm from 5.91 to 6.24 months, which rep-
resents only a 13-day advantage in overall survival (Moore et al.,
2007). It should be noted that in all the mentioned studies with
erlotinib no biomarker was used for patient selection.
How should we interpret the above described results? Shall we
conclude that EGFR-targeted therapies have a minor impact on
survival in advanced cancer patients? A more detailed analysis of
the clinical data, however, leads to an alternative interpretation,
namely, that EGFR-targeted therapies may beneﬁt only a subpop-
ulation of patients – those whose tumors show EGFR oncogene
addiction.
HIGH-RESPONDER PATIENTS PROVIDE CLINICAL EVIDENCES
OF EGFR ONCOGENE ADDICTION
The 1.2 month increase in MST observed for the combination
of cetuximab with chemotherapy in the FLEX trial, conducted in
EGFR-expressing NSCLC patients, was obtained from the analysis
of the intent-to-treat population. With this type of data analysis,
the Kaplan–Meier survival curves for the treatment and control
arms start to separate after 7 months, a time point at which both
arms had about a 60% survival rate (hazard ratio (HR) = 0.871,
p = 0.044). However, when the analysis was carried out separately
for the low and high EGFR-expression tumors, the curves showed
quite different outcomes. For low EGFR-expression tumors no
difference was found between the treatment and control arms
(HR = 0.99, p = 0.88), whereas for high EGFR-expression tumors
there is an evident early separation of the survival curves (approx-
imately after 4 months) and a signiﬁcant survival advantage for
the group receiving cetuximab plus chemotherapy (HR = 0.73,
p = 0.011; Pirker et al., 2009).
A similar phenomenon of time-delayed separation of the PFS
Kaplan–Meier curves was observed with erlotinib used as mainte-
nance therapy after ﬁrst-line chemotherapy in NSCLC patients.
In this case, stratiﬁcation according to EGFR-mutation status
gives rise to two subpopulations with quite different clinical
responses to erlotinib (Pérol et al., 2012). Likewise, in the SAT-
URN trial, a profound predictive effect on PFS of erlotinib relative
to placebo was observed in the EGFR mutation-positive sub-
group (HR = 0.1, p = 0.001), whereas a lower clinical beneﬁt was
observed for thewild-type EGFR subgroup (HR=0.78, p=0.0185;
Cappuzzo et al., 2010). In the study conducted by Shepherd
et al. (2005), the likelihood of a response to erlotinib among
patients with NSCLC was higher among patients with adeno-
carcinoma [objective response rate (ORR) = 13.9% for erlotinib,
versus 4.1% for placebo], and therefore adenocarcinoma was asso-
ciated with survival beneﬁt. Interestingly, in NSCLC patients,
EGFR-activating mutations are found mostly in those with adeno-
carcinomas (Rosell et al., 2009). Overall, activating mutations in
the tyrosine kinase domain of EGFR seem to increase sensitivity
to erlotinib in advanced NSCLC patients in terms of response rate
and PFS.
In patients with locoregionally advanced head and neck can-
cer, the combination of cetuximab with radiotherapy conferred
roughly a 20-month increase in MST, as quoted above. It should
be noted, however, that this advantage was limited to patients with
oropharynx tumors, which were irradiated with a regimen includ-
ing concomitant boost (Bonner et al., 2006). It has been reported
that high EGFR expression correlates with resistance to radiother-
apy (Jedlinski et al., 2013), therefore blocking the EGFR signaling
would induce radio-sensitivity. We would speculate that the oppo-
site effect also takes place, i.e., under RT tumors with high EGFR
expression, such as oropharynx tumors (Luedke et al., 2012), may
become even more EGFR-addicted.
In mCRC cetuximab in combination with FOLFIRI for
ﬁrst-line treatment provides a therapeutic beneﬁt in a patient
subpopulation having EGFR-positive tumors (as deﬁned based
on immunohistochemical evidence of EGFR expression) and
wild-type Kras gene expression, for whom the Kaplan–Meier
progression-free and overall survival curves show an early separa-
tion (Van Cutsem et al., 2009). Thus, EGFR expression, although
a necessary condition, is not sufﬁcient to ensure therapeutic ben-
eﬁt. This is explained by the fact that Kras mutations that turn
downstream signaling independent of EGFR activation provide
an alternative, escape route to satisfy the addiction to the EGFR
signaling pathway. It is tempting to speculate that the relative
abundance of tumor cells with activating mutations in the EGFR
or in Kras that is found in some tumors, e.g., mCRC, may result
from a Darwinian process under the selective pressure exerted by
ﬁrst-line chemotherapy, with higher probabilities of occurrence in
adenocarcinomas. Another interesting phenomenon observed in
the clinic in mCRC is that 20% of the patients that are refractory
to irinotecan respond to the combinatorial therapy of cetuximab
plus irinotecan (Cunningham et al., 2004). A plausible interpreta-
tion is that in these patients, resistance to irinotecan is associated
to an increased addiction to the EGFR, which becomes impaired
upon cetuximab treatment.
EVIDENCES OF ONCOGENE ADDICTION IN
EGFR-OVEREXPRESSING TUMORS FROM OUR CLINICAL
EXPERIENCE WITH NIMOTUZUMAB
Nimotuzumab (also known as h-R3) is a humanized anti-EGFR
mAb (Mateo et al., 1997) developed at the Center of Molecular
Immunology in Havana, Cuba. Since 1998, nimotuzumab has
been extensively tested in 28 completed clinical trials in Cuba (10),
Canada (4), US (1), China (2), Germany (4), India (4), Japan
(2), and South Korea (1). During 2012, 29 clinical trials were
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ongoing in Cuba (8) and other 10 countries: Brazil (4), China
(8), Germany (1), India (2), Indonesia (1), Japan (2), Mexico (1),
and Singapore (2). Nine of them correspond to phase III or phase
IV trials. It is estimated that roughly 30,000 patients have been
treated with the antibody worldwide. Currently, nimotuzumab is
indicated for the treatment of patients bearing advanced head and
neck, nasopharyngeal tumors, adult high grade glioma, children
glioma, and advanced esophageal cancer; and has been registered
in more than 30 developing countries, including Brazil, China,
and India.
Several pieces of information have been published so far indi-
cating that nimotuzumab has a better clinical effect in tumors that
over-express the EGFR. Rodríguez et al. (2010) conducted a phase
II clinical trial in 106 advanced SCCHN patients, mostly unﬁt
for chemo-radiotherapy, to assess the efﬁcacy of nimotuzumab
in combination with radiotherapy. In the intent-to-treat analysis,
the median survival for patients in the nimotuzumab and con-
trol (receiving RT and placebo) groups were 12.5 and 9.5 months,
respectively. EGFR expression was evaluated in tumor biopsies
from 55 patients before enrollment in the trial and separate sur-
vival analyses were done for patients showing at least a weak EGFR
expression and for EGFR-negative subjects. For EGFR-positive
patients (as determined by immunohistochemical staining using a
qualitative scale), a signiﬁcant improvement in MST was observed
within the group treated with nimotuzumab as compared to those
from the control group (16.5 versus 7.2 months, p = 0.0038),
whereas no signiﬁcant advantage was seen for EGFR-negative
patients. A similar behavior was observed in a phase IIB clinical
trial where 92 treatment-naïve patients with advanced head and
neck squamous cell carcinoma received standard therapy either
with or without nimotuzumab (Basavaraj et al., 2010). Here also,
EGFR expression showed a signiﬁcant correlationwith patient sur-
vival in patients treated with nimotuzumab and chemoradiation
(p = 0.02).
In another study, 63 patients with non-resectable, esophageal
cancer of epithelial origin received nimotuzumab in combination
with radiation and chemotherapy, or radiation and chemother-
apy alone (Ramos-Suzarte et al., 2012). The objective response
rates per protocol were 47.8 versus 15.4% (p = 0.014) for the
nimotuzumab and control groups, respectively, while the disease
control rates (DCRs) were 60.9 and 26.9% (p = 0.017). Tumor
EGFR expression at baseline was evaluated for 18 patients (13
from the nimotuzumab arm and 5 from the control arm). The
EGFR expression was classiﬁed as high in 10 out of the 13 patients
treated with nimotuzumab (77%) and in 4 out of the 5 con-
trol subjects (80%). For patients that over-express the EGFR,
the objective response rate was 60% and DCR was 80%, which
improves on the response and DCR seen in the per-protocol
population.
Finally, in a phase II clinical trial conducted by Kim et al.
(2011) in gastric cancer patients refractory to 5Fu-based ther-
apy, no signiﬁcant PFS and overall survival beneﬁt was found
in the intent-to-treat population. As in the previous studies, the
baseline EGFR expression was evaluated in a group of patients
and, again, PFS and overall survival showed a large trend toward
survival beneﬁt for those subjects with medium and high EGFR
expression.
In the particular case of nimotuzumab, the relationship
between the levels of EGFR expression and clinical beneﬁt may
have an explanation at the molecular level, based on the “interme-
diate” afﬁnity of this antibody (Crombet et al., 2004). SPR/biacore
experiments showed that the nimotuzumab Fab fragment has a
KD of the order of 10−8 M; that is, an order of magnitude weaker
than cetuximab Fab’s KD (Talavera et al., 2009). In in vitro exper-
iments, binding of nimotuzumab and subsequent inhibition of
the EGFR phosphorylation was detected only for tumor cell lines
with medium or high levels of EGFR expression (104 receptors
per cell or higher). Furthermore, the Fab fragments bound only
to A431 cells – those with the highest EGFR expression level. In
contrast, cetuximab Fab fragments were able to bind to tumor cells
with lower EGFR expression levels (Garrido et al., 2011b). These
results sustain the idea that nimotuzumab requires bivalent bind-
ing for stable attachment and therefore would bind preferentially
to tumor cells having a medium or high surface density of EGFR
molecules. They also explain the low toxicity proﬁle showed by
this antibody in the clinical practice. Several other properties of
nimotuzumab that may contribute to its clinical effects have been
discussed in a recent review (Perez et al., 2011).
Nimotuzumab’s low toxicity proﬁle has made possible the
intent of using an anti-EGFR agent in continuous, long-term treat-
ment (lasting several months, and a few years in several cases),
which has so far been administered to a few hundred advanced
cancer patients (Perez et al., 2011). For example, in the prospec-
tive clinical study by Saurez et al. (2009) that included 22 pediatric
patients with brain tumors, 10 of these patients received around
30 or more nimotuzumab doses, which in terms of treatment time
corresponds to 1 year or even longer. The median overall survival
was increased from barely a few weeks to 19 months.
The frequently observed disease stabilization and increase of
overall survival resulting from such chronic treatment suggest
that certain level of oncogene addiction is maintained in those
tumors during long periods. Disease stabilization might result
from controlling effects on cancer stem cells and modulation
of the malignant phenotype, and/or enhancement of the nat-
ural anti-tumor immune response, as will be discussed further
below.
HOW TO PREDICT EGFR-ONCOGENE ADDICTION IN THE
CLINICAL SETTING?
“NAÏVE” VERSUS “ADAPTIVE” ONCOGENE ADDICTION
The phenomenon of EGFR oncogene addiction seems to have
several ways of manifesting in the clinic. A ﬁrst difference can
be observed between patients that are being subjected to ﬁrst-line
therapy and patients that have become refractory to previous ther-
apies. In the ﬁrst case we would say that we are in the presence of
a “naïve” oncogene addiction, i.e., an addiction that arises during
tumor progression, whereas the second case would correspond to
an “adaptive” addiction, which develops as a resistant mechanism
driven by chemo- or radiotherapy.
Naïve EGFR addiction reveals in locally advanced SCC (for
example, SCCHN, and the SCC histological subtype of NSCLC),
mostly in tumors having EGFR over-expression, as evidenced
by the clinical responses observed in patients upon treatment
with anti-EGFR agents (Bonner et al., 2006; Pirker et al., 2012).
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Emergence of adaptive EGFRaddiction is observed for tumors that
are refractory to chemotherapeutic agents, which then respond to
the combination of chemotherapy with an anti-EGFR agent. This
adaptive addiction is found even in tumors with low to medium
EGFR expression (for example, CRC, and gastric and pancreas
tumors). In this regard, it is worth noting that EGFR expression
is usually assessed by immunohistochemistry in samples coming
from primary tumors, and less often from metastases.
GENETIC MODIFICATIONS LEADING TO EGFR ADDICTION
The investigations on the EGFR and its ligands have been closely
related to oncology since their very ﬁrst steps in the 1980s. Among
the early discoveries disclosing this relationship are the ﬁnding of
transforming growth factor alpha (TGFα) as part of an autocrine
loop leading to cell malignant transformation (Sporn and Todaro,
1980); the high sequence homology found between the EGFR
and the retroviral oncogenic protein called v-ERBB (Downward
et al., 1984); the increased EGFR expression observed in human
squamous cell lung cancers (Hendler and Ozanne, 1984), and the
subsequent ﬁnding of EGFR aberrant expression and gene ampli-
ﬁcation in a human tumor cell line (Ullrich et al., 1984). Today,
EGFR over-expression is a hallmark in molecular oncology. It is
found in many different types of epithelial derived tumors, often
owing to gene ampliﬁcation (Yarden and Pines, 2012). Gene tran-
scription regulation by microRNAs, such as miR-128b, is another
cause of EGFR over-expression (Weiss et al., 2008). miR-128b loss-
of-heterozygosity has been found in NSCLC patients and has been
shown to be positively correlated with clinical response and sur-
vival following geﬁtinib treatment (Weiss et al., 2008). Several
other EGFR genetic alterationswith oncogenic potential have been
reported; for example, deletion mutants in glioblastoma multi-
forme (GBM; deletion of exons 2–7, denoted EGFRvIII) and in
NSCLC (exon 19), and activating kinase domain mutations in
NSCLC, for example, the leucine-to-argine substitution at position
858 (L858R; Rosell et al., 2007).
RESISTANCE MECHANISMS TO EGFR-TARGETED THERAPIES ARE A
MANIFESTATION OF ONCOGENE ADDICTION
Treating an EGFR-addicted tumor with an anti-EGFR agent cre-
ates a selection pressure favoring the survival of those cells that are
able to avoid the effect of the drug; that is, those cells that ﬁnd an
escape mechanism to satisfy their addiction. In one type of mech-
anism, the EGFR evades the drug via mutations that impair drug
binding or enhance receptor functioning. The former is the case of
the S492R mutant, which confers resistance to cetuximab since the
mutation is located in its binding epitope on the EGFR external
domain (Montagut et al., 2012); whereas the later is the case of the
T790M mutant (mutation in the kinase domain), which confers
resistance to geﬁtinib or erlotinib in lung adenocarcinomas (Pao
et al., 2005) by stabilizing the active tyrosine kinase conformation
and enhancing ATP binding (Yoshikawa et al., 2013).
In a second type of resistance mechanism, the effect of the
drug is evaded by making irrelevant the function of the EGFR
itself, while ensuring downstream signaling via the PI3K/AKT or
RAS/RAF/MEK/ERK pathways. In CRC patients, KRAS mutations
that constitutively activate this enzyme produce a primary resis-
tance to EGFR-targeted mAbs (Lièvre et al., 2006). Activation of
compensatory signaling pathways, like the PI3K/Akt pathway, is
also a way to bypass a blocked EGFR. Inactivating mutations in
PTEN (phosphatase and tensin homolog), which has a tumor
suppressor function, produce such activation of the PI3K/Akt
survival pathway, causing resistance to TKIs and anti-human epi-
dermal growth factor receptor-2 (anti-HER2) antibodies (Garrett
and Arteaga, 2011). Other members of the ERBB family may play
important roles in activating compensatory signals; for example,
acquired resistance to cetuximab in CRC has been linked to acti-
vation of ERBB2 signaling (Yonesaka et al., 2011), while acquired
resistance of lung tumors to geﬁtinib involves activation of the
PI3K pathway through ERBB3 (Engelman et al., 2007).
EVALUATION OF RESPONSE PREDICTOR BIOMARKERS
Different biological substrata might support EGFR addiction in
different stages of the disease and in different tumor localizations,
and in consequence, different response predictor and treatment
selection biomarkers would be needed. In 2009 the FDA updated
the registration labels for panitumumab and cetuximab, speci-
fying that they are approved for the treatment of CRC tumors
expressingwild-typeKRAS. Thiswas indeed amilestone in theway
toward the development of personalized EGFR-targeted therapies.
In addition to the KRAS mutation status, it has been reported that
expression of epiregulin and amphiregulin is a response predictor
in metastatic CRC patients treated with cetuximab (Khambata-
Ford et al., 2007). Another case of successful use of a biomarker
has been the assessment of activating EGFR mutations in NSCLC
(for example, L858R), which predicts response to STKIs. These
mutations are more frequent in the adenocarcinoma subtypes of
NSCLC (Rosell et al., 2009).
In spite of the variety of scenarios, EGFR over-expression
seems to be a common hallmark of EGFR oncogene addiction,
although the existent disagreements concerning the appropriate
method for measuring and classifying the level of EGFR expres-
sion have yielded contradictory results and discrepancies in regard
to its relevance. Other practical difﬁculties may hinder the use of
this biomarker, for example, determining the presence of adap-
tive EGFR addiction would demand the evaluation of biomarkers
in refractory metastatic lesions, which is not always feasible. In
general, we need a more systematic and comprehensive analysis
of both EGFR signaling-activating and resistance-inducing muta-
tions, as well as an analysis of the activation of compensatory
signaling pathways that may result upon treatment with EGFR-
targeted agents, in order to validate in the clinical setting the
already known or suspected predictor biomarkers, and to deﬁne
new ones.
EGFR ONCOGENE ADDICTION MAY REFLECT THE
INTERCONNECTION OF SEVERAL CELLULAR PATHWAYS
THE NEED FOR AN INCREASED GLUCOSE METABOLISM MAY
REINFORCE EGFR ONCOGENE ADDICTION
It iswell-known that EGFRactivationupon ligandbinding induces
survival signaling through the PI3K/Akt pathway, which upregu-
lates anti-apoptotic factors (Engelman, 2009). Therefore abroga-
tion of EGFR activation by targeting either the ectodomain or
the kinase intracellular domain favors the induction of apoptotic
cell death. In a recent report, a different mechanism to induce cell
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death was uncovered. The EGFR was shown to prevent autophagic
cell death by maintaining the intracellular glucose level, most
likely through stabilizing interactions with the sodium/glucose
co-transporter 1 (SGLT1; Weihua et al., 2008). Abrogating the
EGFR gene expression by small interfering RNA (siRNA) resulted
in loss of SGLT1, leading to a decrease in the intracellular glu-
cose level. Since tumor micro-environment is characterized by
hypoxia and nutrient starvation, pathways that guarantee an
active glucose transport become critical for tumor cell survival.
In this context, the stabilizing effect exerted by the EGFR on the
sodium/glucose co-transporters might contribute to reinforce the
addiction of tumor cells to this oncogene. Recent clinical studies
have demonstrated that co-expression of EGFR and SGLT1 is asso-
ciated with differentiation and prognosis of human tumors (Guo
et al., 2011; Hanabata et al., 2012). Moreover, ionizing irradiation
of human lung adenocarcinoma cells increased SGLT1 expres-
sion as a survival mechanism that depends on EGFR signaling
(Huber et al., 2012).
The molecular details of the interaction between the EGFR
and SGLT1 remain unknown. It is known, however, that the sta-
bilizing effect on SGLT1 depends on the extracellular region of
the EGFR, while being independent of the activity of the tyrosine
kinase domain. In a plausible model, these molecules would inter-
act, either directly or indirectly, in the context of amacromolecular
assembly at the cell membrane. Speciﬁc anti-EGFR antibodies
might then affect such interactions by increasing receptor inter-
nalization, thus destabilizing the macromolecular assembly and
leading to a down-regulation of the SGLT1 expression. Following
the above reasoning, tumorswithhighEGFRexpression and show-
ingpositive positron emission tomography (PET) imageswould be
highly sensitive to EGFR antagonistic antibodies. Here, neverthe-
less, we have to take into account that 2-(18F)-2-deoxy-D-glucose
(the glucose analog used in PET imaging) is a poor substrate for
SGLT1 (Wright et al., 2011) and, therefore, PET studies with this
tracer would not be measuring the glucose uptake via the SGLT1
co-transporter.
FUNCTIONAL INHIBITION OF AN “ADDICTIVE” ONCOGENE MAY
INDUCE IMMUNOGENIC CELL DEATH
Experiments using a murine EGFR (mEGFR)-antagonistic anti-
body in a syngeneic preclinical model demonstrated that the
anti-metastatic effect produced by treatment with this mAb is
mediated by T cells, since depletion of CD4+ and CD8+ T cells
abrogated the anti-tumor effect (Garrido et al., 2007). In a differ-
ent experimental setting, mice immunized with the extracellular
domain of the mEGFR developed a strong antibody response with
high EGFR-antagonistic activity, which resulted in reduction of
lung metastases (Ramírez et al., 2006, 2008). This anti-metastatic
effect of the mEGFR vaccine also was abolished by in vivo deple-
tion of the CD8+ T lymphocyte subpopulation (Aguiar Alpizar
et al., 2012). Furthermore, it was demonstrated that an anti-EGFR
antibody, but not a STKI, promotes an immunogenic cell death
in a Lewis lung carcinoma model, involving induction of a CTL
response in vivo (Garrido et al., 2011a). Remarkably, the immuno-
genic effect found in these experiments was independent of the
effector functions of the antibody, since the Fab’(2) fragments
were shown to induce immunogenic apoptosis. T cell responses
have been measured and have been found to be relevant also in
other models of oncogene addiction, as in a recent study demon-
strating that CD4+ T cells are required for tumor regression upon
inactivation of the MYC or BCR–ABL oncogenes in mouse models
of T cell acute lymphoblastic lymphoma and pro-B cell leukemia,
respectively (Rakhra et al., 2010).
All together, these experimental results suggest that functional
inhibition of an “addictive” oncogene may trigger an immuno-
genic cell death which activates a T cell-mediated anti-tumor
response, although as evidenced in the above described experi-
ment with a STKI, not every inhibition mechanism would yield
this effect. Enhancement of the natural anti-tumor immunity,
if sustained, might contribute to a long-lasting control of the
disease by counteracting the tumor resistance to the targeted
therapy.
EGFR ONCOGENE ADDICTION MAY BE RELEVANT FOR TUMOR
INITIATING CELLS
Different lines of experimental evidences point to the existence of
EGFR addiction in tumor initiating cells derived from neural tis-
sue. GBM derived tumor initiating cells that express EGFR display
themostmalignant functional andmolecular phenotype.Modula-
tionof EGFRexpression in these cells by gain- and loss-of-function
strategies enhances or reduces their tumorigenic ability, suggesting
that EGFR plays a fundamental role in gliomagenesis (Ayuso-
Sacido et al., 2010; Mazzoleni et al., 2010). Noteworthy, PI3K and
the mammalian target of rapamycin (mTOR) are involved in the
epidermal growth factor (EGF)-mediated maintenance of neu-
ral progenitor cells, supporting their self-renewal capacity and
non-differentiated state (Sato et al., 2010). Indeed, brain cancer
stem cells are preferentially sensitive to Akt signaling inhibition,
which reduces the number of viable cells relative to matched non-
stem cancer cells. The describedmechanism suggests a preferential
induction of apoptosis and a suppression of neurosphere forma-
tion, driving an increase in survival of immune-compromised
mice bearing human glioma xenografts (Eyler et al., 2008). GBM
CD133-positive tumor initiating cells have proven to be radio-
resistant and most likely are the source of tumor recurrence after
radiation (Bao et al., 2006). It has been shown, however, that
combination of anti-EGFR antibodies, namely cetuximab and
nimotuzumab with radiotherapy reduces the number of CD133-
positive tumor initiating cells (Diaz Miqueli et al., 2009). This
suggests that radiation-based therapy reinforces the EGFR onco-
gene addiction of neural cancer stem cells, adding a rationale for
combining anti-EGFR antibodies and radiotherapy to treat brain
tumors.
The relevance of the EGFR signaling pathway in the sur-
vival, maintenance, and function of cancer stem cells have been
demonstrated also for head and neck and breast tumors (Hardy
et al., 2010; Abhold et al., 2012; Yan et al., 2012). Activation of
EGFR in head and neck SCC in vitro resulted in increased tumor
sphere formation, while treatment with geﬁtinib, also in vitro,
decreased the capacity of putative cancer stem cells to invade and
made them more sensitive to cisplatin-induced death (Abhold
et al., 2012). In breast cancer cells, EGFR signaling activation
can induce epithelial to mesenchymal transition (EMT), favor-
ing invasion and metastasis along with increased expression of
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genes associated with self-renewal, increased percentage of stem-
like cells, in vitro sphere formation and in vivo tumor growth
(Del Vecchio et al., 2012; El-Haibi et al., 2012). In aggressive
inﬂammatory breast cancer, inhibition of the EGFR reversed
the mesenchymal phenotype of cancer cells to a less aggressive
andpotentiallymore chemotherapy-sensitive epithelial phenotype
(Zhang et al., 2009).
Modulation of the malignant phenotype resulting from EGFR
inhibition can be seen as a manifestation of the phenomenon of
EGFR oncogene addiction, which in this case has a particular
translational relevance because we may infer from it that chronic
use of EGFR-targeted therapy would have a controlling effect on
EGFR-addicted metastases. Our clinical experiences using nimo-
tuzumab for long-term treatment of advanced cancer patients, as
discussed above, give certain support to this hypothesis.
COMBINATORIAL TARGETED THERAPY CAN MODULATE
ONCOGENE ADDICTION: FRIEND OR FOE?
In combining targeting agents different strategies can be fol-
lowed. One approach is to combine agents acting either on the
same or on different targets, but in the same signaling pathway.
Another approach is to combine agents acting on targets in dif-
ferent pathways or cellular mechanisms. The rationale behind the
ﬁrst approach would be that cancer cells are addicted to speciﬁc
signaling pathways rather than to a single oncogene, therefore
the combination of agents acting on the same pathway may have
a stronger inhibitory effect (Weinstein and Joe, 2006). On the
other hand, signaling pathways have evolved to adapt to rare
mutations, therefore they would be more sensitive to multiple
hits (Yarden and Pines, 2012). The second approach may, the-
oretically, involve cellular pathways related to the complexity of
the tumor biology; for example, targeting molecules involved in
cancer-related inﬂammation (Mantovani et al., 2008) and tumor
metabolic re-programming (Kroemer and Pouyssegur, 2008). But
as we discussed above, we still lack knowledge for the rational
design of such combinatorial targeted therapies. To date, the com-
bination studies performed with anti-EGFR drugs, even though
guided by these strategies, have at the same time been biased by
the available therapeutic agents.
DOES MULTIPLE-TARGETING OF EGFR IMPAIR RESISTANCE
INDUCTION?
The combination of an anti-EGFR antibody with a STKI, namely
cetuximab and erlotinib, has been attempted only in a couple of
early phase trials designed to optimize the dose and treatment
schedule. In one of these studies, 19 patients with lung adeno-
carcinoma and clinically deﬁned acquired resistance to erlotinib
were treated with 100 mg erlotinib daily, along with cetuximab
every 2 weeks in three escalating dose cohorts (250–500 mg/m2).
At these doses and treatment schedule no radiographic responses
were seen, so the authors concluded that the combination had no
signiﬁcant activity in patients with acquired resistance to erlotinib
(Janjigian et al., 2011). In the second study, 22 patients with
advanced solid malignancies (including 14 patients with NSCLC)
who had failed standard chemotherapies received escalating doses
of cetuximab (100–250 mg/m2i.v. weekly) in combination with
a ﬁxed dose of erlotinib (150 mg daily, orally) until disease
progression or unacceptable toxicity (Guarino et al., 2009). The
authors concluded that dual EGFR inhibition with cetuximab
and erlotinib was feasible, but no conclusions were obtained
on response rates and other clinical endpoints. The question
on whether combining different EGFR antagonists may impair
resistance induction, remains to be answered.
SIMULTANEOUS TARGETING OF EGFR AND VEGF IN THE CLINIC HAS
BEEN DISAPPOINTING
Targeting agents directed at the vascular endothelial growth factor
(VEGF), such as bevacizumab, and to the EGFR, such as cetuximab
and panitumumab, have become part of the standard treatment
of mCRC. Earlier experimental work demonstrated that acquired
resistance to anti-EGFRantibodies can bemediated by constitutive
up-regulation of VEGF gene expression (Viloria-Petit et al., 2001;
Crombet-Ramos et al., 2002), suggesting that simultaneous target-
ing of EGFR andVEGFmay impair resistance induction. However,
several recent phase III trials have shown a detrimental effect from
adding an anti-EGFR antibody to standard chemotherapy plus
bevacizumab. In the CAIRO trial (Tol et al., 2009), patients with
previously untreated mCRC were randomized to capecitabine,
oxaliplatin, and bevacizumab (CB regimen) or to the same reg-
imen plus weekly cetuximab (CBC regimen). The results of this
trial were disappointing – the median PFS was 10.7 months in the
CB group versus 9.4 months in the CBC group (p = 0.01), and
the quality-of-life scores were lower in the CBC group. The overall
survival and response rates did not differ signiﬁcantly in the two
groups. In another trial, advanced CRC patients were random-
ized to either the combination of bevacizumab, leucovorin, and
5-ﬂuorouracil (5-FU), or the same combination plus cetuximab.
The 12-month PFS for the two groups were 45 versus 32%, ORR
– 52 versus 41%, DCRs – 87 versus 83%, and the median overall
survival times were 21 versus 19.5 months. In summary, the com-
bination including cetuximab was not superior. The conclusion
after these trials is that cetuximab and bevacizumab should not be
used concurrently in metastatic CRC (Saltz et al., 2012).
Similar results were obtained in the phase III Panitumumab
Advanced Colorectal Cancer Evaluation (PACCE) trial, that inves-
tigatedpanitumumabadded to a regimen combiningbevacizumab
with chemotherapy. This trial resulted in unacceptable toxicities
in the investigation arm and no differences in efﬁcacy, leading
to discontinuation of the study. Overall, the addition of pani-
tumumab reduced both the median PFS and the median overall
survival.
Combining bevacizumab with a STKI has been also assayed.
In a phase III trial, patients with metastatic pancreatic adenocar-
cinoma were randomly assigned to gemcitabine, erlotinib, and
bevacizumab, or gemcitabine and erlotinib. Adding bevacizumab
to gemcitabine–erlotinib signiﬁcantly improved PFS (HR = 0.73;
95% CI, 0.61 to 0.86; p = 0.0002). However, the differences in
MST (7.1 versus 6.0 months for the bevacizumab and placebo
arms, respectively; HR = 0.89, p = 0.2087), were not statistically
signiﬁcant (Van Cutsem et al., 2009).
Not all the combination experiences have been negative,
though. In particular, some encouraging results have been seen in
theNSCLC settingwhen combining bevacizumab and erlotinib. In
the BeTa phase III trial (Herbst et al., 2011), patientswith recurrent
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or refractory NSCLC that had failed a ﬁrst-line treatment were
allocated to receive erlotinib plus bevacizumab or erlotinib plus
placebo. The median overall survival did not differ between the
two groups (9.3 versus 9.2months), but PFS seemed to be longer in
the bevacizumab group (3.4 versus 1.7 months) and the objective
response rates suggested some clinical activity of the bevacizumab
plus erlotinib combination. In the ATLAS study, designed to
evaluate the combination of bevacizumab with erlotinib versus
bevacizumab alone in patients with stage IIIb/IV NSCLC, the pri-
mary endpoint of improving PFS was met (4.8 versus 3.7 months)
and the safety proﬁle for the combination was consistent with the
proﬁles known for the two drugs (Kabbinavar et al., 2010).
In general, the results obtained so far from combinatorial
EGFR-targeted therapy are not encouraging, except for the com-
bination of bevacizumab and erlotinib in advanced NSCLC. As
described above, the combination of bevacizumabwith cetuximab
or panitumumab showed deleterious effect inmCRC.Noteworthy,
it has been suggested that cetuximab in mCRC may activate tumor
promoting M2 macrophages (Pander et al., 2011), which in turn
induce chronic inﬂammation in the tumor micro-environment,
that would facilitate tumor progression (Mantovani et al., 2008).
RATIONAL DESIGN OF COMBINATORIAL TARGETED THERAPIES
SHOULD DRIVE DRUG DEVELOPMENT
Some stimulating results have recently been obtained in the pre-
clinical setting with combinations of antibodies targeting one or
two members of the ErbB family. Combinations of different, non-
competitive antibodies targeting the EGFR (including cetuximab
and panitumumab, but not together in the same combination
since they compete with each other) inhibited tumor growth in
triple-negative breast cancermodels by promoting amore efﬁcient
down-regulation and degradation of the receptor (Ferraro et al.,
2013). Likewise, combination of cetuximab with an anti-HER4
antibody andwith radiotherapywasmore effective in reducing cell
survival and tumor growth using head and neck cancer cell lines
(Barnea et al., 2013). Testing of any of these combinations in the
clinic, however, is hampered by the fact that in all the assayed drug
dyads at most only one of the antibodies is a registered therapeutic
agent.
The clinical results obtained so far from combinatorial thera-
pies reinforce the main idea discussed in the previous section that
the oncogene addiction phenomenon may involve the intercon-
nection of several cellular pathways. EGFR-targeted therapy might
thenmodulate (either increase or decrease) the addiction of tumor
cells to other oncogenes. Predicting whether a given combination
will produce this phenomenon of trans-modulation of oncogene
addiction is currently a very difﬁcult task due the complexity of
the intracellular signaling networks. A tempting approach involv-
ing targets that are not in cancer cells is to combine anti-EGFR
agents with drugs that may enhance the immune system response
against the tumor; for example, with an anti-cytotoxic T lym-
phocyte antigen 4 (anti-CTLA-4) antibody such as ipilimumab
(Lipson and Drake, 2011).
Studying in the clinical setting the resistance mechanisms that
emerge from the use of EGFR-targeted agents would provide
important clues for the rational design of effective combinatorial
therapies. Probably, some of the envisioned combinations will
demand drugs that are not yet in the clinic, while some other
designs will require totally new drugs. Thus, the quest for better
combinatorial therapies would drive the development of new ther-
apeutic agents with the express purpose of using them not alone,
but in speciﬁc drug combinations.
CONCLUDING REMARKS
Epidermal growth factor receptor-targeted therapies, although
they have provided clinical beneﬁt, have not completely fulﬁlled
our expectations so far. A lesson from the available clinical data
is that a new clinical research paradigm is required to evalu-
ate targeted therapies. In particular, the concept of personalized
medicinehasnot been yet translated to thedesignof pivotal clinical
trials.
In our view, clinical investigation of EGFR-targeted therapies
should follow these principles: (1) Treatment should be indicated
based on an operational deﬁnition of EGFR oncogene addiction,
which should be split according to clinical characteristics like
tumor type, disease staging and previous treatments, as well as
the existing knowledge on resistance mechanisms; (2) The design
of combinatorial therapies that target, in addition to the EGFR,
other oncogenes should be based on experimental and clinical
evidences showing that these oncogenes play a role in the acquired
resistance to the EGFR-targeting agent. This way, EGFR-targeted
therapy would be translated into a set of treatment niches deﬁned
under the approach of “personalized medicine.”
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